1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington. 2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
*Corresponding Author: Anne McTiernan, Public Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Avenue North, P.O. Box 19024, Seattle, WA 98109. E-mail: [email protected] ...
Background:. A critical component of oncogenesis and cancer progression is metabolic re-programming of cells to enable continuous growth. Oncogenic activated signaling pathways can drive de novo ...
University of Arkansas for Medical Sciences, Little Rock, AR.
Search for other works by this author on: ...
Suzhou Genhouse Pharmaceutical Co., Ltd., Suzhou, China.
Cancer Res (2025) 85 (8_Supplement_1): 6376.
Laboratory Dr. Pachmann, Bayreuth, Germany.
Cellentia Inc., Foster City, CA. Search for other works by this author on: ...
Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York ...
Fudan University Shanghai Cancer Center, Shanghai, China.
PDL1V is a novel vedotin antibody drug-conjugate (ADC) currently in Phase I clinical development for advanced solid tumors as a monotherapy or in combination with pembrolizumab (NCT05208762). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback